Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, neurology and rare diseases, announces today the signing of a collaboration agreement with
The collaboration aims to profile downstream signaling pathways of a set of GPCRs potentially involved across multiple therapeutic areas, using Domain's bioSens-All technology consisting of BRET based cellular assays enabling them to investigate native form of GPCRs.
Domain Therapeutics is eligible to receive from
The profiling may enable Domain Therapeutics and
This collaboration builds upon a 2017 collaboration between
'We are pleased to continue to build upon our previous collaboration with Domain Therapeutics. We believe that Domain's GPCR technology has the potential to help us identify drug targets across multiple therapeutic areas, including internal medicine, which could, in turn, serve as the basis of potential future breakthrough research projects,' said
'We are proud to work alongside
About G Protein-Coupled Receptors
GPCRs belong to the family of membrane receptors and constitute one of the main classes of therapeutic targets for many indications. The binding of a hormone or a specific ligand to a receptor's binding site activates one or several pathways for intracellular signaling. This enables the cell to provide an adapted response to the change in its environment. The drugs that target GPCRs represent about 30% of all treatments on the market, but only address 28% of the GPCRs. Thus, GPCRs remain largely underexploited to date. Domain Therapeutics proposes novel drug candidates for the remaining 70%, thanks to its unique drug discovery engine using technologies such as bioSens-All.
Contact:
Tel: 450-726-4565
Email: direction@bioquebec.com
(C) 2020 Electronic News Publishing, source